deltatrials
Completed PHASE3 NCT00314860

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)

Sponsor: GlaxoSmithKline

Conditions Restless Legs Syndrome Restless Legs Syndrome (RLS)
Interventions ropinirole Extended Release (XR)
Updated 6 times since 2017 Last updated: Oct 17, 2016 Started: Feb 28, 2006 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

A PHASE3 clinical study on Restless Legs Syndrome and Restless Legs Syndrome (RLS), this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Amsterdam, Netherlands, Anaheim, United States, Anzin, France, Auchenflower, Australia, Barcelona, Spain, Bergen, Norway, Berlin, Germany, Birmingham, United States, Blackpool, United Kingdom and 78 more location s